CPF1 complexes with reduced indel activity

Patent metadata

Field	Value
Publication number	US-12344838-B2
Application number	US-202217666248-A
Country	US
Kind code	B2
Filing date	Feb 7, 2022
Priority date	Apr 19, 2016
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

First claim

What is claimed:

1. An engineered guide RNA (gRNA) capable of forming a CRISPR-Cpf1 complex with a Cpf1 effector protein and directing the CRISPR-Cpf1 complex to a target sequence; wherein the gRNA comprises a dead guide sequence capable of reducing indel activity of the CRISPR-Cpf1 complex; wherein
(a) said guide sequence is 10-14 nucleotides in length and complementary to the target sequence, or
(b)said guide sequence comprises a matching section and a mismatching section with the matching section being 10-16 contiguous nucleotides in length and complementary to the target sequence, wherein the mismatching section is present on the 3′ end of the gRNA.

2. The gRNA of claim 1 , wherein indel activity is reduced by at least 90%, or at least 95%, or at least 97%, or at least 99%.

3. The gRNA of claim 1 , wherein indel activity is detected by purifying and amplifying a CRISPR target site for a gene and forming heteroduplexes with primers amplifying the CRISPR target site, and treating the amplification products with a nuclease.

4. The gRNA of claim 1 , wherein indel activity is detected by a BLISS assay.

5. The gRNA of claim 1 , wherein said guide sequence of (a) is 12-14 nucleotides in length and complementary to the target sequence.

6. The gRNA of claim 1 , wherein said guide sequence of (b) comprises a matching section and a mismatching section with the matching section being 12-15 contiguous nucleotides in length and complementary to the target sequence.

7. The gRNA of claim 1 , wherein the guide sequence of (b) comprises 10-16 contiguous nucleotides complementary to the target sequence adjacent to a PAM sequence.

8. The gRNA of claim 1 , wherein the guide sequence of (b) comprises 12-15 contiguous nucleotides complementary to the target sequence adjacent to a PAM sequence.

9. A composition comprising the gRNA of claim 1 , and further comprising a Cpf1 effector protein capable of forming a CRISPR-Cpf1 complex with the gRNA.

10. The composition of claim 9 , wherein the Cpf1 effector protein is FnCpf1, AsCpf1, or LbCpf1.

11. The composition of claim 9 , wherein the Cpf1 effector protein is a nuclease capable of cleaving both DNA strands.

12. The composition of claim 9 , wherein the Cpf1 effector protein comprises at least one mutation and is a nickase capable of cleaving one DNA strand.

13. The composition of claim 9 , wherein the Cpf1 effector protein comprises one or more nuclear localization signals.

14. The composition of claim 9 , wherein a loop of the gRNA is engineered to comprise an aptamer sequence capable of binding to an adaptor protein, wherein the composition further comprises the adaptor protein linked to a heterologous functional domain.

15. The composition of claim 14 , wherein the adaptor protein comprises MS2, PP7, QP, F2, GA, fr, JP501, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, ϕCb5, ϕCb8r, ϕCb12r, ϕCb23r, 7s, or PRR1.

16. The composition of claim 14 , wherein the heterologous functional domain is an activator domain, a repressor domain, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a deaminase, a light inducible/controllable domain, or a chemically inducible/controllable domain.

17. The composition of claim 14 , wherein the heterologous functional domain is a transcriptional activation domain and comprises VP64, p65, MyoD1, HSF1, RTA, or SET7/9.

18. The composition of claim 14 , wherein the heterologous functional domain is a transcriptional repressor domain and comprises a KRAB domain, NuE domain, NcoR domain, SID domain, or a SID4X domain.

19. The composition of claim 9 , wherein the Cpf1 is linked to a heterologous functional domain.

20. The composition of claim 19 , wherein the heterologous functional domain is an activator domain, a repressor domain, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a deaminase, a light inducible/controllable domain, or a chemically inducible/controllable domain.

21. The composition of claim 19 , wherein the heterologous functional domain is a transcriptional activation domain and comprises VP64, p65, MyoD1, HSF1, RTA, or SET7/9.

22. The composition of claim 19 , wherein the heterologous functional domain is a transcriptional repressor domain and comprises a KRAB domain, NuE domain, NcoR domain, SID domain, or a SID4X domain.

23. The composition of claim 9 , wherein the composition comprises a second gRNA capable of forming a second CRISPR-Cpf1 complex with a Cpf1 effector protein and directing the second CRISPR-Cpf1 complex to a second target sequence, wherein the second gRNA comprises a guide sequence capable of hybridizing to the second target sequence while permitting detectable indel activity by the second CRISPR-Cpf1 complex.

24. The composition of claim 9 , wherein the composition comprises a plurality of gRNAs each having a dead guide sequence.

25. A method for modifying a genomic locus, which comprises administering the composition of claim 9 to a eukaryotic cell comprising the genomic locus.

26. The method according to claim 25 , wherein the genomic locus is modified by transcriptional gene activation, transcriptional gene inhibition, or cleavage in the genomic locus.

27. A vector system comprising a nucleic acid molecule encoding the gRNA of claim 1 .

28. The vector system of claim 27 , wherein the vector system comprises a nucleic acid molecule encoding a Cpf1 effector protein.

29. A delivery particle comprising the composition of claim 9 .

30. A eukaryotic cell comprising the composition of claim 9 .

31. The gRNA of claim 1 , wherein the guide sequence is 14 nucleotides in length and complementary to the target sequence.

32. The gRNA of claim 1 , wherein the guide sequence is 24 nucleotides in length, and wherein the guide sequence of (b) comprises a matching section and a mismatching section with the matching section being 14 contiguous nucleotides in length and complementary to the target sequence, wherein the mismatching section is 10 contiguous mismatching nucleotides and present on the 3′ end of the gRNA.

Assignees

• Broad Inst Inc
• Massachusetts Inst Technology

Inventors

• Zhang Feng
• Zetsche Bernd
• Yan Winston
• Sanjana Neville Espi
• Jones Sara

Classifications

• C12Y305/04005

  Cytidine deaminase (3.5.4.5) · CPC title

• C12N15/907

  in mammalian cells · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title